<div id="hidden-data" style="display: none">

    <div id="profile-popup-1" class="popup-container">
        <div class="popup-row">
            <div class="popup-column w-25">
                <div class="inner-popup-row">
                    <img id="popup-image"
                        src="https://images.squarespace-cdn.com/content/v1/5a961859620b8571f03ac13e/85cc0aad-91c9-429a-adb0-740e6224faa3/Bill_McClellan_transparent.png?format=500w"
                        style="width:100%">
                    <div class="popup-mini-bio">
                        <h3>BILL MCCLELLAN</h3>
                        <h4>CPA</h4>
                    </div>
                </div>
            </div>
            <div class="popup-column w-75">
                <div class="inner-popup-text">
                    <p>Most recently, Bill was the Chief Financial Officer of Aerin
                        Medical Inc., which makes products to treat chronic nasal conditions non-invasively. </p>
                    <p>Prior to Aerin, Bill spent 13 years as CFO and Executive VP of
                        Finance for On-X Life Technologies, Inc., a heart surgery medical device company which was sold
                        to
                        Artvivion (CryoLife) in 2016. </p>
                    <p>Early in his career, Bill spent nine years specializing in
                        healthcare with the public accounting firm PriceWaterhouseCoopers (formerly Price Waterhouse)
                        followed by
                        executive management positions with PhyCor, Inc., Physicians Trust, Inc., US Orthopedics, Inc.,
                        and Acxiom
                        Corporation. </p>
                    <p>Bill served on the boards of directors of Apollo Endosurgery Inc.
                        and Reata Pharmaceuticals Inc, both publicly-traded companies, and chaired their Audit
                        Committees until
                        their acquisitions by Boston Scientific and Biogen, respectively. Bill has also served on
                        numerous other
                        boards of directors or advisory boards including public, private, non-profit and private
                        equity/venture
                        capital.</p>
                </div>
            </div>
        </div>
    </div>

    <div id="profile-popup-2" class="popup-container">
        <div class="popup-row">
            <div class="popup-column w-25">
                <div class="inner-popup-row">
                    <img id="popup-image"
                        src="https://images.squarespace-cdn.com/content/v1/5a961859620b8571f03ac13e/80903f39-84ff-4f1a-bc76-9b6db4ca3b52/Diane_Gomez-Thinnes_transparent.png?format=500w"
                        style="width:100%">
                    <div class="popup-mini-bio">
                        <h3>DIANE GOMEZ-THINNES</h3>
                        <div class="image-subtitle sqs-dynamic-text" data-width-percentage="37.7"
                            style="font-size: max(0.75rem, 37.7%);" id="yui_3_17_2_1_1714502057232_152">
                            <p>Chief Commerical Officer, Better Therapeutics </p>
                            <p>U.S. President, Galderma </p>
                            <p>WW President, Mentor (J&amp;J) </p>
                            <p>Strategic Marketing, Cordis &amp; Ethicon
                                (J&amp;J)</p>
                        </div>
                    </div>
                </div>
            </div>
            <div class="popup-column w-75">
                <div class="inner-popup-text">

                    <p>Diane recently served as Chief Commercial Officer for
                        Better Therapeutics, where she focused on the company’s commercial capabilities and led the
                        launch of AspyreRx, an FDA-authorized prescription digital therapeutic delivering cognitive
                        behavioral therapy for the treatment of Type II Diabetes. </p>
                    <p>Prior to Better Therapeutics, was the U.S. President of
                        Galderma responsible for integrating its aesthetic, consumer care and prescription medicines
                        business units following its divestiture from Nestlé. </p>
                    <p>From 2003 to 2021,
                        Diane spent nearly two decades at Johnson &amp; Johnson in strategic and commercial roles in its
                        medtech sector ultimately serving as the Worldwide President of Mentor, a women’s surgical
                        breast aesthetics business. </p>
                    <p>Diane began at J&amp;J as a member of the Cordis team who
                        launched Cypher, the first drug eluting stent. At Ethicon, Diane led the Biosurgery franchise
                        and commercialized the Evarrest fibrin sealant patch for rapid hemostasis of problematic
                        bleeding in surgery. </p>
                    <p>Diane serves as an Executive Strategic Advisor to InSoma
                        Biotech, an early-stage start-up developing novel injectable material to mimic human tissue. She
                        serves on the Board of Directors for Workforce Solutions Dallas, appointed by Dallas Mayor Eric
                        Johnson. Diane also sits on the Board of the Association of Latino Princeton Alumni.</p>

                </div>
            </div>
        </div>
    </div>

    <div id="profile-popup-3" class="popup-container">
        <div class="popup-row">
            <div class="popup-column w-25">
                <div class="inner-popup-row">
                    <img id="popup-image"
                        src="https://images.squarespace-cdn.com/content/v1/5a961859620b8571f03ac13e/df7dd471-2e3d-472e-8f11-8ecf6d80630c/Glen_Kashuba_transparent.png?format=500w"
                        style="width:100%">
                    <div class="popup-mini-bio">
                        <h3>GLEN KASHUBA</h3>
                        <div class="image-subtitle sqs-dynamic-text" data-width-percentage="37.7"
                            style="font-size: max(0.75rem, 37.7%);">
                            <p>CEO, Highridge Medical </p>
                            <p>CEO, Cerapedics </p>
                            <p>WW President, Spine and Bone, Biomet </p>
                            <p>WW President for Cordis Endovascular and
                                Neurovascular (J&amp;J) </p>
                            <p>WW President for Codman Neuro (J&amp;J) U.S.
                                President of DePuy Spine (J&amp;J)</p>
                        </div>
                    </div>
                </div>
            </div>
            <div class="popup-column w-75">
                <div class="inner-popup-text">

                    <p>Glen is currently the CEO of Highridge Medical,
                        previously, the spine division of ZimVie. </p>
                    <p>Prior to Highridge Medical, Glen was the CEO of Cerapedics
                        Inc., a privately held Ortho-biologics company focused on developing and commercializing
                        peptide-enhanced bone graft products. </p>
                    <p>Glen has also served as Worldwide President for Spine
                        &amp; Bone Healing Technologies, Inc., a division of Biomet Inc. Additionally, Glen concurrently
                        served as Senior Vice President on Biomet’s Worldwide Operating Board, encompassing the
                        Orthopedics, Spine, Trauma, Biologics, and Sports Medicine businesses. Previously, he has held a
                        number of Divisional president roles at Johnson &amp; Johnson where he served as Worldwide
                        President for Cordis Endovascular and Neurovascular and as Worldwide President for Codman Neuro
                        Sciences and U.S. President of DePuy Spine. </p>
                    <p>In addition to his corporate roles, Glen has concurrently
                        managed a contract manufacturing business, Ortho-Craft that was acquired by Paragon Medical in
                        2005. He has also served several board of director positions including SpineView, Palyon
                        Medical, Veniti Medical, Cambridge Endoscopic Devices, and Extremity Medical.</p>

                </div>
            </div>
        </div>
    </div>

    <div id="profile-popup-4" class="popup-container">
        <div class="popup-row">
            <div class="popup-column w-25">
                <div class="inner-popup-row">
                    <img id="popup-image"
                        src="https://images.squarespace-cdn.com/content/v1/5a961859620b8571f03ac13e/d60d134b-b12e-4f72-bcb9-a1272dfbb7c9/Glenn_Mattes_transparent.png?format=500w"
                        style="width:100%">
                    <div class="popup-mini-bio">
                        <h3>BILL MCCLELLAN</h3>
                        <div class="image-subtitle sqs-dynamic-text" data-width-percentage="37.7"
                            style="font-size: max(0.75rem, 37.7%);">
                            <p class="" style="white-space:pre-wrap;">CEO, kaleo (Acquired) </p>
                            <p class="" style="white-space:pre-wrap;">Director, Avenu Meidcal (Acquired) </p>
                            <p class="" style="white-space:pre-wrap;">Vice President, Cardiac Rhythm Management, Boston
                                Scientific</p>
                        </div>
                    </div>
                </div>
            </div>
            <div class="popup-column w-75">
                <div class="inner-popup-text">

                    <p class="" style="white-space:pre-wrap;">Glenn Mattes has more than 30 years of healthcare
                        enterprise leadership and executive experience. He has served in executive capacities in large
                        pharmaceutical companies, biotech and device focused companies in both public and private
                        domains. </p>
                    <p class="" style="white-space:pre-wrap;">Most recently, Glenn was CEO at TFF, Inc., a
                        pharmaceutical company developing a novel inhalation therapy technology platform with an IPO in
                        2023. Glenn has been involved at a number of development stage companies as CEO and Board level.
                    </p>
                    <p class="" style="white-space:pre-wrap;">Glenn’s specific company experience includes Johnson &amp;
                        Johnson, Rhône Poulenc Rorer, ConvaTec, Candel, Centocor, TFF, Arno Therapeutics, Translational
                        Sciences, The Gores Group, and the Clayton Foundation for Research. </p>
                    <p class="" style="white-space:pre-wrap;">Glenn was appointed to the President’s Advisory Committee
                        on HIV/AIDS by President George W. Bush and the U.S. Secretary of Health and Human Services.</p>

                </div>
            </div>
        </div>
    </div>

    <div id="profile-popup-5" class="popup-container">
        <div class="popup-row">
            <div class="popup-column w-25">
                <div class="inner-popup-row">
                    <img id="popup-image"
                        src="https://images.squarespace-cdn.com/content/v1/5a961859620b8571f03ac13e/f48f1f61-9fc6-4054-a2a3-f51705141408/K+Ballinger+transparent.png?format=500w"
                        style="width:100%">
                    <div class="popup-mini-bio">
                        <h3>BILL MCCLELLAN</h3>
                        <h4>CPA</h4>
                    </div>
                </div>
            </div>
            <div class="popup-column w-75">
                <div class="inner-popup-text">
                    <p>Most recently, Bill was the Chief Financial Officer of Aerin
                        Medical Inc., which makes products to treat chronic nasal conditions non-invasively. </p>
                    <p>Prior to Aerin, Bill spent 13 years as CFO and Executive VP of
                        Finance for On-X Life Technologies, Inc., a heart surgery medical device company which was sold
                        to
                        Artvivion (CryoLife) in 2016. </p>
                    <p>Early in his career, Bill spent nine years specializing in
                        healthcare with the public accounting firm PriceWaterhouseCoopers (formerly Price Waterhouse)
                        followed by
                        executive management positions with PhyCor, Inc., Physicians Trust, Inc., US Orthopedics, Inc.,
                        and Acxiom
                        Corporation. </p>
                    <p>Bill served on the boards of directors of Apollo Endosurgery Inc.
                        and Reata Pharmaceuticals Inc, both publicly-traded companies, and chaired their Audit
                        Committees until
                        their acquisitions by Boston Scientific and Biogen, respectively. Bill has also served on
                        numerous other
                        boards of directors or advisory boards including public, private, non-profit and private
                        equity/venture
                        capital.</p>
                </div>
            </div>
        </div>
    </div>

    <div id="profile-popup-6" class="popup-container">
        <div class="popup-row">
            <div class="popup-column w-25">
                <div class="inner-popup-row">
                    <img id="popup-image"
                        src="https://images.squarespace-cdn.com/content/v1/5a961859620b8571f03ac13e/85cc0aad-91c9-429a-adb0-740e6224faa3/Bill_McClellan_transparent.png?format=500w"
                        style="width:100%">
                    <div class="popup-mini-bio">
                        <h3>BILL MCCLELLAN</h3>
                        <h4>CPA</h4>
                    </div>
                </div>
            </div>
            <div class="popup-column w-75">
                <div class="inner-popup-text">
                    <p>Most recently, Bill was the Chief Financial Officer of Aerin
                        Medical Inc., which makes products to treat chronic nasal conditions non-invasively. </p>
                    <p>Prior to Aerin, Bill spent 13 years as CFO and Executive VP of
                        Finance for On-X Life Technologies, Inc., a heart surgery medical device company which was sold
                        to
                        Artvivion (CryoLife) in 2016. </p>
                    <p>Early in his career, Bill spent nine years specializing in
                        healthcare with the public accounting firm PriceWaterhouseCoopers (formerly Price Waterhouse)
                        followed by
                        executive management positions with PhyCor, Inc., Physicians Trust, Inc., US Orthopedics, Inc.,
                        and Acxiom
                        Corporation. </p>
                    <p>Bill served on the boards of directors of Apollo Endosurgery Inc.
                        and Reata Pharmaceuticals Inc, both publicly-traded companies, and chaired their Audit
                        Committees until
                        their acquisitions by Boston Scientific and Biogen, respectively. Bill has also served on
                        numerous other
                        boards of directors or advisory boards including public, private, non-profit and private
                        equity/venture
                        capital.</p>
                </div>
            </div>
        </div>
    </div>

    <div id="profile-popup-7" class="popup-container">
        <div class="popup-row">
            <div class="popup-column w-25">
                <div class="inner-popup-row">
                    <img id="popup-image"
                        src="https://images.squarespace-cdn.com/content/v1/5a961859620b8571f03ac13e/85cc0aad-91c9-429a-adb0-740e6224faa3/Bill_McClellan_transparent.png?format=500w"
                        style="width:100%">
                    <div class="popup-mini-bio">
                        <h3>BILL MCCLELLAN</h3>
                        <h4>CPA</h4>
                    </div>
                </div>
            </div>
            <div class="popup-column w-75">
                <div class="inner-popup-text">
                    <p>Most recently, Bill was the Chief Financial Officer of Aerin
                        Medical Inc., which makes products to treat chronic nasal conditions non-invasively. </p>
                    <p>Prior to Aerin, Bill spent 13 years as CFO and Executive VP of
                        Finance for On-X Life Technologies, Inc., a heart surgery medical device company which was sold
                        to
                        Artvivion (CryoLife) in 2016. </p>
                    <p>Early in his career, Bill spent nine years specializing in
                        healthcare with the public accounting firm PriceWaterhouseCoopers (formerly Price Waterhouse)
                        followed by
                        executive management positions with PhyCor, Inc., Physicians Trust, Inc., US Orthopedics, Inc.,
                        and Acxiom
                        Corporation. </p>
                    <p>Bill served on the boards of directors of Apollo Endosurgery Inc.
                        and Reata Pharmaceuticals Inc, both publicly-traded companies, and chaired their Audit
                        Committees until
                        their acquisitions by Boston Scientific and Biogen, respectively. Bill has also served on
                        numerous other
                        boards of directors or advisory boards including public, private, non-profit and private
                        equity/venture
                        capital.</p>
                </div>
            </div>
        </div>
    </div>

    <div id="profile-popup-8" class="popup-container">
        <div class="popup-row">
            <div class="popup-column w-25">
                <div class="inner-popup-row">
                    <img id="popup-image"
                        src="https://images.squarespace-cdn.com/content/v1/5a961859620b8571f03ac13e/85cc0aad-91c9-429a-adb0-740e6224faa3/Bill_McClellan_transparent.png?format=500w"
                        style="width:100%">
                    <div class="popup-mini-bio">
                        <h3>BILL MCCLELLAN</h3>
                        <h4>CPA</h4>
                    </div>
                </div>
            </div>
            <div class="popup-column w-75">
                <div class="inner-popup-text">
                    <p>Most recently, Bill was the Chief Financial Officer of Aerin
                        Medical Inc., which makes products to treat chronic nasal conditions non-invasively. </p>
                    <p>Prior to Aerin, Bill spent 13 years as CFO and Executive VP of
                        Finance for On-X Life Technologies, Inc., a heart surgery medical device company which was sold
                        to
                        Artvivion (CryoLife) in 2016. </p>
                    <p>Early in his career, Bill spent nine years specializing in
                        healthcare with the public accounting firm PriceWaterhouseCoopers (formerly Price Waterhouse)
                        followed by
                        executive management positions with PhyCor, Inc., Physicians Trust, Inc., US Orthopedics, Inc.,
                        and Acxiom
                        Corporation. </p>
                    <p>Bill served on the boards of directors of Apollo Endosurgery Inc.
                        and Reata Pharmaceuticals Inc, both publicly-traded companies, and chaired their Audit
                        Committees until
                        their acquisitions by Boston Scientific and Biogen, respectively. Bill has also served on
                        numerous other
                        boards of directors or advisory boards including public, private, non-profit and private
                        equity/venture
                        capital.</p>
                </div>
            </div>
        </div>
    </div>

    <div id="profile-popup-9" class="popup-container">
        <div class="popup-row">
            <div class="popup-column w-25">
                <div class="inner-popup-row">
                    <img id="popup-image"
                        src="https://images.squarespace-cdn.com/content/v1/5a961859620b8571f03ac13e/85cc0aad-91c9-429a-adb0-740e6224faa3/Bill_McClellan_transparent.png?format=500w"
                        style="width:100%">
                    <div class="popup-mini-bio">
                        <h3>BILL MCCLELLAN</h3>
                        <h4>CPA</h4>
                    </div>
                </div>
            </div>
            <div class="popup-column w-75">
                <div class="inner-popup-text">
                    <p>Most recently, Bill was the Chief Financial Officer of Aerin
                        Medical Inc., which makes products to treat chronic nasal conditions non-invasively. </p>
                    <p>Prior to Aerin, Bill spent 13 years as CFO and Executive VP of
                        Finance for On-X Life Technologies, Inc., a heart surgery medical device company which was sold
                        to
                        Artvivion (CryoLife) in 2016. </p>
                    <p>Early in his career, Bill spent nine years specializing in
                        healthcare with the public accounting firm PriceWaterhouseCoopers (formerly Price Waterhouse)
                        followed by
                        executive management positions with PhyCor, Inc., Physicians Trust, Inc., US Orthopedics, Inc.,
                        and Acxiom
                        Corporation. </p>
                    <p>Bill served on the boards of directors of Apollo Endosurgery Inc.
                        and Reata Pharmaceuticals Inc, both publicly-traded companies, and chaired their Audit
                        Committees until
                        their acquisitions by Boston Scientific and Biogen, respectively. Bill has also served on
                        numerous other
                        boards of directors or advisory boards including public, private, non-profit and private
                        equity/venture
                        capital.</p>
                </div>
            </div>
        </div>
    </div>

    <div id="profile-popup-10" class="popup-container">
        <div class="popup-row">
            <div class="popup-column w-25">
                <div class="inner-popup-row">
                    <img id="popup-image"
                        src="https://images.squarespace-cdn.com/content/v1/5a961859620b8571f03ac13e/85cc0aad-91c9-429a-adb0-740e6224faa3/Bill_McClellan_transparent.png?format=500w"
                        style="width:100%">
                    <div class="popup-mini-bio">
                        <h3>BILL MCCLELLAN</h3>
                        <h4>CPA</h4>
                    </div>
                </div>
            </div>
            <div class="popup-column w-75">
                <div class="inner-popup-text">
                    <p>Most recently, Bill was the Chief Financial Officer of Aerin
                        Medical Inc., which makes products to treat chronic nasal conditions non-invasively. </p>
                    <p>Prior to Aerin, Bill spent 13 years as CFO and Executive VP of
                        Finance for On-X Life Technologies, Inc., a heart surgery medical device company which was sold
                        to
                        Artvivion (CryoLife) in 2016. </p>
                    <p>Early in his career, Bill spent nine years specializing in
                        healthcare with the public accounting firm PriceWaterhouseCoopers (formerly Price Waterhouse)
                        followed by
                        executive management positions with PhyCor, Inc., Physicians Trust, Inc., US Orthopedics, Inc.,
                        and Acxiom
                        Corporation. </p>
                    <p>Bill served on the boards of directors of Apollo Endosurgery Inc.
                        and Reata Pharmaceuticals Inc, both publicly-traded companies, and chaired their Audit
                        Committees until
                        their acquisitions by Boston Scientific and Biogen, respectively. Bill has also served on
                        numerous other
                        boards of directors or advisory boards including public, private, non-profit and private
                        equity/venture
                        capital.</p>
                </div>
            </div>
        </div>
    </div>

    <div id="profile-popup-11" class="popup-container">
        <div class="popup-row">
            <div class="popup-column w-25">
                <div class="inner-popup-row">
                    <img id="popup-image"
                        src="https://images.squarespace-cdn.com/content/v1/5a961859620b8571f03ac13e/85cc0aad-91c9-429a-adb0-740e6224faa3/Bill_McClellan_transparent.png?format=500w"
                        style="width:100%">
                    <div class="popup-mini-bio">
                        <h3>BILL MCCLELLAN</h3>
                        <h4>CPA</h4>
                    </div>
                </div>
            </div>
            <div class="popup-column w-75">
                <div class="inner-popup-text">
                    <p>Most recently, Bill was the Chief Financial Officer of Aerin
                        Medical Inc., which makes products to treat chronic nasal conditions non-invasively. </p>
                    <p>Prior to Aerin, Bill spent 13 years as CFO and Executive VP of
                        Finance for On-X Life Technologies, Inc., a heart surgery medical device company which was sold
                        to
                        Artvivion (CryoLife) in 2016. </p>
                    <p>Early in his career, Bill spent nine years specializing in
                        healthcare with the public accounting firm PriceWaterhouseCoopers (formerly Price Waterhouse)
                        followed by
                        executive management positions with PhyCor, Inc., Physicians Trust, Inc., US Orthopedics, Inc.,
                        and Acxiom
                        Corporation. </p>
                    <p>Bill served on the boards of directors of Apollo Endosurgery Inc.
                        and Reata Pharmaceuticals Inc, both publicly-traded companies, and chaired their Audit
                        Committees until
                        their acquisitions by Boston Scientific and Biogen, respectively. Bill has also served on
                        numerous other
                        boards of directors or advisory boards including public, private, non-profit and private
                        equity/venture
                        capital.</p>
                </div>
            </div>
        </div>
    </div>

    <div id="profile-popup-12" class="popup-container">
        <div class="popup-row">
            <div class="popup-column w-25">
                <div class="inner-popup-row">
                    <img id="popup-image"
                        src="https://images.squarespace-cdn.com/content/v1/5a961859620b8571f03ac13e/85cc0aad-91c9-429a-adb0-740e6224faa3/Bill_McClellan_transparent.png?format=500w"
                        style="width:100%">
                    <div class="popup-mini-bio">
                        <h3>BILL MCCLELLAN</h3>
                        <h4>CPA</h4>
                    </div>
                </div>
            </div>
            <div class="popup-column w-75">
                <div class="inner-popup-text">
                    <p>Most recently, Bill was the Chief Financial Officer of Aerin
                        Medical Inc., which makes products to treat chronic nasal conditions non-invasively. </p>
                    <p>Prior to Aerin, Bill spent 13 years as CFO and Executive VP of
                        Finance for On-X Life Technologies, Inc., a heart surgery medical device company which was sold
                        to
                        Artvivion (CryoLife) in 2016. </p>
                    <p>Early in his career, Bill spent nine years specializing in
                        healthcare with the public accounting firm PriceWaterhouseCoopers (formerly Price Waterhouse)
                        followed by
                        executive management positions with PhyCor, Inc., Physicians Trust, Inc., US Orthopedics, Inc.,
                        and Acxiom
                        Corporation. </p>
                    <p>Bill served on the boards of directors of Apollo Endosurgery Inc.
                        and Reata Pharmaceuticals Inc, both publicly-traded companies, and chaired their Audit
                        Committees until
                        their acquisitions by Boston Scientific and Biogen, respectively. Bill has also served on
                        numerous other
                        boards of directors or advisory boards including public, private, non-profit and private
                        equity/venture
                        capital.</p>
                </div>
            </div>
        </div>
    </div>

    <div id="profile-popup-13" class="popup-container">
        <div class="popup-row">
            <div class="popup-column w-25">
                <div class="inner-popup-row">
                    <img id="popup-image"
                        src="https://images.squarespace-cdn.com/content/v1/5a961859620b8571f03ac13e/85cc0aad-91c9-429a-adb0-740e6224faa3/Bill_McClellan_transparent.png?format=500w"
                        style="width:100%">
                    <div class="popup-mini-bio">
                        <h3>BILL MCCLELLAN</h3>
                        <h4>CPA</h4>
                    </div>
                </div>
            </div>
            <div class="popup-column w-75">
                <div class="inner-popup-text">
                    <p>Most recently, Bill was the Chief Financial Officer of Aerin
                        Medical Inc., which makes products to treat chronic nasal conditions non-invasively. </p>
                    <p>Prior to Aerin, Bill spent 13 years as CFO and Executive VP of
                        Finance for On-X Life Technologies, Inc., a heart surgery medical device company which was sold
                        to
                        Artvivion (CryoLife) in 2016. </p>
                    <p>Early in his career, Bill spent nine years specializing in
                        healthcare with the public accounting firm PriceWaterhouseCoopers (formerly Price Waterhouse)
                        followed by
                        executive management positions with PhyCor, Inc., Physicians Trust, Inc., US Orthopedics, Inc.,
                        and Acxiom
                        Corporation. </p>
                    <p>Bill served on the boards of directors of Apollo Endosurgery Inc.
                        and Reata Pharmaceuticals Inc, both publicly-traded companies, and chaired their Audit
                        Committees until
                        their acquisitions by Boston Scientific and Biogen, respectively. Bill has also served on
                        numerous other
                        boards of directors or advisory boards including public, private, non-profit and private
                        equity/venture
                        capital.</p>
                </div>
            </div>
        </div>
    </div>

    <div id="profile-popup-14" class="popup-container">
        <div class="popup-row">
            <div class="popup-column w-25">
                <div class="inner-popup-row">
                    <img id="popup-image"
                        src="https://images.squarespace-cdn.com/content/v1/5a961859620b8571f03ac13e/85cc0aad-91c9-429a-adb0-740e6224faa3/Bill_McClellan_transparent.png?format=500w"
                        style="width:100%">
                    <div class="popup-mini-bio">
                        <h3>BILL MCCLELLAN</h3>
                        <h4>CPA</h4>
                    </div>
                </div>
            </div>
            <div class="popup-column w-75">
                <div class="inner-popup-text">
                    <p>Most recently, Bill was the Chief Financial Officer of Aerin
                        Medical Inc., which makes products to treat chronic nasal conditions non-invasively. </p>
                    <p>Prior to Aerin, Bill spent 13 years as CFO and Executive VP of
                        Finance for On-X Life Technologies, Inc., a heart surgery medical device company which was sold
                        to
                        Artvivion (CryoLife) in 2016. </p>
                    <p>Early in his career, Bill spent nine years specializing in
                        healthcare with the public accounting firm PriceWaterhouseCoopers (formerly Price Waterhouse)
                        followed by
                        executive management positions with PhyCor, Inc., Physicians Trust, Inc., US Orthopedics, Inc.,
                        and Acxiom
                        Corporation. </p>
                    <p>Bill served on the boards of directors of Apollo Endosurgery Inc.
                        and Reata Pharmaceuticals Inc, both publicly-traded companies, and chaired their Audit
                        Committees until
                        their acquisitions by Boston Scientific and Biogen, respectively. Bill has also served on
                        numerous other
                        boards of directors or advisory boards including public, private, non-profit and private
                        equity/venture
                        capital.</p>
                </div>
            </div>
        </div>
    </div>
</div>
<style>
    .popup-container {
        display: flex;
    }

    .popup-row {
        display: flex;
        justify-content: center;
        align-items: center;
        height: 100%;
    }

    .w-25 {
        width: 25%;
    }

    .w-75 {
        width: 75%;
    }

    .popup-column {
        display: flex;
        justify-content: center;
        align-items: center;
        height: 100%;
    }

    img {
        width: 100%;
        height: 100%;
    }
</style>